Alumis Inc. (ALMS)
NASDAQ • Healthcare
Last close at October 23, 2026 at 20:00 UTC
Metrics Over Time
Where the Money Goes
Q2 2026Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Nov 12
in 18 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Alumis trailed consensus on both EPS and revenue in the second fiscal quarter of 2026, reported August 13, 2026, as revenue fell 38% to about $1.7 million (down from roughly $2.7 million a year ago) while EPS of -$1.11 trailed the -$0.77 estimate by -$0.34 and revenue of $1.7 million trailed the $3.7 million estimate (-54%). With gross profit also around $1.7 million, the quarter’s results still centered on a sizable expense base for its autoimmune-disorder pipeline, driving operating income to negative roughly $148.9 million and net income to negative about $142.2 million, versus net income of roughly $59.3 million a year ago. Consensus for the next period calls for EPS of -$0.73 on revenue of $1.9 million.
Next report — what to expect
Alumis Inc. (ALMS) reports on November 12, 2026. Wall Street is looking for EPS of -$0.73 on revenue of $1.9 million. For trailing context, revenue declined -37.7% year over year last quarter. Alumis has beaten EPS in 2 of its 8 most recent quarters.
About Alumis Inc.
Alumis Inc. is a NASDAQ-listed biotechnology company developing and aiming to commercialize medicines for autoimmune disorders. In FY2025, the company recorded $24.1 million in revenue. Its work centers on immune-pathway drug candidates that span autoimmune disease, central nervous system inflammation, and related immune dysfunction.
Today's Snapshot
The day ended with ALMS 0.6% lower at 6.78, in line with a weaker sector. Trading was lighter than usual, with volume about two-thirds of its usual level.
Trading Volume
Below 10d avg (1.8M)
1.2M
vs S&P 500 Today
Inline with Market
-0.07%
Updated: October 23, 2026 at 20:20 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$6.70 - $16.86Sell
- RSI (14)33.62Neutral
- Stochastic %K (14, 3, 3)61.03Neutral
- MACD Level (12, 26)-1.22Neutral
Peers & Related Assets
Get premium market insights delivered directly to your inbox.